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Herein, updated evidence-based recommendations for the diagnosis,
assessment, prevention, and treatment of hypertension in Canadian
adults are detailed. For 2014, 3 existing recommendations were
modiﬁed and 2 new recommendations were added. The following
recommendations were modiﬁed: (1) the recommended sodium
intake threshold was changed from  1500 mg (3.75 g of salt) to
approximately 2000 mg (5 g of salt) per day; (2) a pharmacotherapy
treatment initiation systolic blood pressure threshold of  160 mm Hg
was added in very elderly (age  80 years) patients who do not have
diabetes or target organ damage (systolic blood pressure target in this
population remains at < 150 mm Hg); and (3) the target population
recommended to receive low-dose acetylsalicylic acid therapy for pri-
mary prevention was narrowed from all patients with controlled hy-
pertension to only those  50 years of age. The 2 new
Executive SummaryRESUME
Ici nous presentons en detail les mises à jour des recommandations
fondees sur des preuves concernant le diagnostic, l’evaluation, la
prevention et le traitement de l’hypertension arterielle des adultes
canadiens. Pour l’annee 2014, 3 recommandations ont ete modiﬁees
et 2 nouvelles recommandations ont ete ajoutees. Les recommanda-
tions suivantes ont ete modiﬁees : 1) les seuils de l’apport
recommande en sodium sont passes de  1500 mg (3,75 g de sel) à
approximativement 2000 mg (5 g de sel) par jour; 2) un seuil de
 160 mm Hg pour la pression arterielle systolique au debut de la
pharmacotherapie a ete ajoute pour les patients très âges ( 80 ans)
n’ayant pas de diabète ou d’atteinte à un organe cible (les valeurs
cibles de pression arterielle systolique chez cette population ont ete
maintenues à < 150 mm Hg); 3) la population cible devant recevoir le
traitement d’acide acetylsalicylique à faible dose pour la preventionObjective: To provide updated 2014 evidence-based rec-
appraised relevant articles using standardized grading algo-
rithms. For pharmacologic interventions, evidence from ran-ommendations for the prevention, diagnosis, assessment, and
treatment of hypertension in adults.
Methods: A medical librarian independently conducted a
MEDLINE search current to August 2013. Reference lists
were reviewed and experts were contacted to identify addi-
tional studies. Content and methodology experts reviewed anddomized trials and systematic reviews of trials were preferred
and changes in cardiovascular morbidity and mortality, and
total mortality, were the primary outcomes of interest. For
health behaviour management, blood pressure (BP)-lowering
was accepted as a primary outcome. In patients with chronic
kidney disease (CKD), progressive renal impairment was
recommendations are: (1) advice to be cautious when lowering systolic
blood pressure to target levels in patients with established coronary
artery disease if diastolic blood pressure is  60 mm Hg because of
concerns that myocardial ischemia might be exacerbated; and (2) the
addition of glycated hemoglobin (A1c) in the diagnostic work-up of
patients with newly diagnosed hypertension. The rationale for these
recommendation changes is discussed. In addition, emerging data on
blood pressure targets in stroke patients are discussed; these data did
not lead to recommendation changes at this time. The Canadian Hy-
pertension Education Program recommendations will continue to be
updated annually.
primaire est passee de tous les patients ayant une hypertension qui
est contrôlee à seulement ceux ayant  50 ans. Les 2 nouvelles
recommandations sont : 1) les conseils de prudence lors de la dimi-
nution de la pression arterielle systolique aux valeurs cibles chez les
patients ayant une coronaropathie etablie si la pression arterielle
diastolique est  60 mm Hg puisque les risques lies à l’ischemie
myocardique pourraient être exacerbes; 2) l’ajout de l’hemoglobine
glyquee (A1c) au bilan diagnostique des patients ayant nouvellement
reçu un diagnostic d’hypertension. Nous discutons des raisons de ces
modiﬁcations des recommandations. Nous discutons egalement des
nouvelles donnees sur les valeurs cibles de pression arterielle chez les
patients ayant subi un accident vasculaire cerebral; ces donnees n’ont
actuellement pas entraîne de modiﬁcations des recommandations.
Les recommandations du Programme educatif canadien sur l’hy-
pertension continueront d’être mises à jour annuellement.
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2014 CHEP Recommendationsaccepted as a clinically relevant primary outcome. All rec-
ommendations were graded according to the strength of the
supporting evidence, and newly proposed recommendations
or changes to existing recommendations were discussed at a
consensus conference held October 15-16, 2013, in Montreal,
Canada. Proposed changes to the recommendations accepted
at the consensus conference were subsequently voted on by
the 69 members of the Canadian Hypertension Education
Program (CHEP) Recommendations Task Force (RTF).
Recommendations that received at least 70% task force
approval were accepted as ﬁnal.Recommendations
Diagnosis and assessment
One new recommendation related to the addition of gly-
cated hemoglobin (A1C) as a diagnostic screening test in
newly diagnosed hypertensive patients was added.Prevention and treatment
For 2014, 3 existing recommendations were modiﬁed and
1 new recommendation was added. Modiﬁcations to existing
recommendations include: (1) a change in the recommended
sodium intake threshold to approximately 2000 mg (5 g of
salt) per day from  1500 mg (3.75 g of salt); (2) the addition
of a systolic BP (SBP)  160 mm Hg pharmacotherapy
treatment initiation threshold in very elderly (age  80 years)
patients who do not have diabetes or target organ damage
(with the SBP target in this population remaining at < 150
mm Hg); and (3) a modiﬁcation to the target population
recommended to receive low-dose acetylsalicylic acid (ASA)
therapy for primary prevention from all controlled hyperten-
sive patients to those  50 years. The new recommendations
include advice to be cautious when lowering SBP to target
levels in patients with established coronary artery disease
(CAD) if diastolic BP (DBP) is  60 mm Hg because of
concerns that myocardial ischemia might be exacerbated.Updates
CHEP will continue to update recommendations annually.Introduction
Hypertension affects approximately 20% of the Canadian
adult population1,2 and is a major risk factor for cardiovascular
disease, CKD, and death, remaining largely silent until the
development of complications.3,4 Worldwide, high BP affects
more than 40% of adults5 and is the leading global risk factor
for death or disability.6 BP control rates are nearly 65% in
Canada and 13.2% globally.1,5
With the goal of improving hypertension prevention,
detection, assessment, and management in Canadian adults,
the CHEP, with funding from Hypertension Canada, pro-
duces annually updated, evidence-based recommendations for
primary care and other health care providers. This document
outlines all recommendations endorsed by the CHEP RTF
and contains detailed discussion of the evidence base and
rationale for recommendations that have been updated or
newly added for 2014. Discussion of the rationale for rec-
ommendations that remain unchanged is available in previous
publications.7-28 A full set of supplementary tables are avail-
able as an online supplement to this article.
The recommendations detailed herein are intended to guide
health care providers and should not replace sound clinical
judgement. Practitioners are advised to consider patient pref-
erences when applying these recommendations in the care of
their patients and should note that CHEP does not currently
take into account economic considerations when formulating
recommendations. Although individual antihypertensive
agents may be mentioned when discussing evidence, the reader
should assume a class effect, unless otherwise stated.Methods
The CHEP RTF is a multidisciplinary panel of content
and methodological experts comprised of 2 Co-Chairs, a
Central Review Committee (CRC), and 23 subgroups. Each
subgroup addresses a distinct content area in hypertension (see
Supplemental Appendix S1 for the current CHEP member-
ship list). Members of the Canadian Task Force on Preventive
Health Care, Canadian Diabetes Association Guidelines
Committee, Canadian Society of Nephrology, Canadian
Stroke Network, Canadian Cardiovascular Society, and the
Canadian Cardiovascular Harmonized National Guideline
Endeavour Initiative regularly collaborate with CHEP mem-
bers to facilitate harmonization of hypertension-related
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CHEP RTF members serve as volunteers for multiple
organizations.
Systematic literature searches current to August 2013 were
performed by a Cochrane Collaboration librarian in MED-
LINE/PubMed using text words and MeSH headings. Search
terms included hypertension[MeSH], hypertens*[ti, ab], and
blood pressure; these were combined with topic-speciﬁc terms.
Bibliographies of identiﬁed articles were also manually
searched. Details of search strategies and retrieved articles are
available on request. Randomized controlled trials and sys-
tematic reviews of randomized trials were reviewed for treat-
ment recommendations and cross-sectional and cohort studies
were reviewed for assessment of diagnosis and prognosis.
Each subgroup examined the search results pertinent to its
content area. Studies that assessed relevant outcomes were
selected for further review. Cardiovascular morbidity and
mortality and total mortality outcomes were prioritized for
pharmacotherapy studies. For health behaviour recommenda-
tions, BP was considered an acceptable surrogate and, in pa-
tients with CKD, progressive renal impairment was considered
to be a clinically important outcome. Study characteristics and
study quality were assessed using prespeciﬁed, standardized
algorithms developed by the CHEP29 for the critical appraisal
of randomized controlled trials and cohort studies. Recom-
mendations were graded according to the strength of their
underlying evidence (for details, see Supplemental Table S1),
ranging from Grade A (strongest evidence, based on high-
quality studies) to Grade D (weakest evidence, based on low
power, imprecise studies, or expert opinion alone). Although
the CHEP does not use the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) recom-
mendation scheme (www.gradeworkinggroup.org), it should
be noted that all CHEP recommendations are considered to be
“strong” in nature (ie, the CHEP refrains from making “weak”
recommendations). Thus, the CHEP grading scheme refers
only to the quality of evidence and not to the relative strength
of the recommendation. For pharmacotherapy recommenda-
tions, as a general rule, the CHEP considers evidence evalu-
ating speciﬁc agents to be generalizable to a “class effect.” For
diuretic therapy, the term “thiazides” refers to hydro-
chlorthiazide (or similar agents) and the term “thiazide-like”
refers to chlorthalidone and indapamide.
Subgroup members, considered content experts in their
ﬁelds, were responsible for reviewing annual search results
and, if indicated, drafting new recommendations or proposing
changes to old recommendations. An independent CRC
consisting of methodological experts with no industry afﬁlia-
tions independently reviewed, graded, and reﬁned proposed
recommendations, which were then presented at a consensus
conference of the RTF in Montreal, Canada on October 16
and 17, 2013. This meeting included the Co-Chairs, CRC,
and members of all subgroups. Further revisions to the pro-
posed recommendations were based on these discussions.
After the consensus meeting, the recommendations were
ﬁnalized and submitted electronically to all 69 voting mem-
bers of the CHEP RTF for approval. Members with potential
conﬂicts of interest recused themselves from voting on speciﬁc
recommendations (a list of conﬂicts is in Supplemental
Appendix S2). Recommendations receiving > 70% approval
passed. The CHEP recommendations process is in accordancewith the AGREE II guidelines30 and has been externally
reviewed. A summary of how the CHEP process aligns with
Appraisal of Guidelines, Research and Evaluation (AGREE) II
may be found online at: http://www.hypertension.ca/en/chep/
overview-a-process agree. Materials to assist with patient and
public education based on these recommendations are freely
available at: http://www.hypertension.ca.The 2014 CHEP Diagnosis and Assessment
Recommendations
I. Accurate measurement of BP
Recommendations
1. Health care professionals who have been speciﬁcally trained
to measure BP accurately should assess BP in all adult
patients at all appropriate visits to determine cardiovascular
risk and monitor antihypertensive treatment (Grade D).
2. Use of standardizedmeasurement techniques (Supplemental
Table S2) is recommended when assessing BP (Grade D).
3. Automated ofﬁce BP measurement (OBPM) can be used
in the assessment of ofﬁce BP (Grade D).
4. When used in proper conditions, automated ofﬁce SBP of
 135 mm Hg or DBP of  85 mm Hg should be
considered analogous to mean awake ambulatory SBP of
 135 mm Hg and DBP of  85 mm Hg, respectively
(Grade D).Background. There are no changes to these recommenda-
tions for 2014.
II. Criteria for diagnosis of hypertension and
recommendations for follow-up (Fig. 1)
Recommendations
1. At initial presentation, patients demonstrating features of a
hypertensive urgency or emergency (Supplemental
Table S3) should be diagnosed as hypertensive and
require immediate management (Grade D).
2. If SBP is  140 mm Hg and/or DBP is  90 mm Hg, a
speciﬁc visit should be scheduled for the assessment of
hypertension (Grade D). If BP is high-normal (SBP 130-
139 mm Hg and/or DBP 85-89 mm Hg), annual follow-
up is recommended (Grade C).
3. At the initial visit for the assessment of hypertension, if
SBP is  140 and/or DBP is  90 mm Hg, at least 2 more
readings should be taken during the same visit using a
validated device and according to the recommended pro-
cedure for accurate BP determination (Supplemental
Table S2). The ﬁrst reading should be discarded and the
latter 2 or more readings averaged. A history and physical
examination should be performed and, if clinically indi-
cated, diagnostic tests to search for target organ damage
(Supplemental Table S4) and associated cardiovascular risk
factors (Supplemental Table S5) should be arranged within
2 visits. Exogenous factors that can induce or aggravate
hypertension should be identiﬁed and addressed if possible
(Supplemental Table S6). Visit 2 should be scheduled
within 1 month (Grade D).
Figure 1. The expedited assessment and diagnosis of patients with hypertension: Focus on validated technologies for BP assessment.
** Thresholds refer to BP values averaged across the corresponding number of visits and not just the most recent ofﬁce visit. ABPM, ambulatory BP
monitoring; BP, blood pressure (mm Hg); DBP, diastolic BP (mm Hg); HBPM, home BP measurement; HTN, hypertension; OBPM, ofﬁce BP
measurement; SBP, systolic BP (mm Hg). Reproduced with permission from the Canadian Hypertension Education Program.
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macrovascular target organ damage, diabetes mellitus, or
CKD (glomerular ﬁltration rate < 60 mL/min/1.73 m2)
can be diagnosed as hypertensive if SBP is  140 mm Hg
and/or DBP is  90 mm Hg (Grade D).
5. At visit 2 for the assessment of hypertension, patients
without macrovascular target organ damage, diabetes
mellitus, or CKD can be diagnosed as hypertensive if the
SBP is  180 mm Hg and/or the DBP is  110 mm Hg
(Grade D). Patients without macrovascular target organ
damage, diabetes mellitus, or CKD but with lower BPlevels should undergo further evaluation using any of the 3
approaches outlined next:
i. OBPM: Using manual OBPM, patients can be diag-
nosed as hypertensive if the SBP is 160 mmHg or the
DBP is  100 mm Hg averaged across the ﬁrst 3 visits,
or if the SBP averages  140 mm Hg or the DBP av-
erages  90 mm Hg averaged across 5 visits (Grade D).
ii. Ambulatory BP monitoring (ABPM): Using ABPM
(see Recommendations in section VIII. ABPM),
patients can be diagnosed as hypertensive if the
mean awake SBP is  135 mm Hg or the DBP is
490 Canadian Journal of Cardiology
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mm Hg or the DBP is  80 mm Hg (Grade C).
iii. Home BP monitoring (HBPM): Using HBPM (see
Recommendations in section VII. HBPM), patients can
be diagnosed as hypertensive if the average SBP is
 135 mm Hg or the DBP is  85 mm Hg (Grade C).
If the average home BP is < 135/85 mm Hg, it is
advisable to either repeat home monitoring to conﬁrm
the home BP is < 135/85 mm Hg or perform 24-hour
ABPM to conﬁrm that the mean 24-hour ABPM is
< 130/80 mm Hg and the mean awake ABPM is
< 135/85 mm Hg before diagnosing white coat hy-
pertension (Grade D).
6. Investigations for secondary causes of hypertension should be
initiated in patients with suggestive clinical and/or laboratory
features (outlined in sections V. Assessment for Renovascular
Hypertension and VI. Endocrine Hypertension) (Grade D).
7. If, at the last diagnostic visit, the patient is not diagnosed as
hypertensive and has no evidence of macrovascular target
organ damage, the patient’s BP should be assessed at yearly
intervals (Grade D).
8. Hypertensive patients actively modifying their health be-
haviours should be followed up at 3- to 6-month intervals.
Shorter intervals (every 1 or 2 months) are needed for
patients with higher BP measurements (Grade D).
9. Patients using antihypertensive drugs should be seen
monthly or every 2 months, depending on the level of BP,
until readings on 2 consecutive visits are below their target
(GradeD). Shorter intervals between visits will be needed for
symptomatic patients and those with severe hypertension,
intolerance to antihypertensive drugs, or target organ dam-
age (Grade D). When the target BP has been reached, pa-
tients should be seen at 3- to 6-month intervals (Grade D).Background. There are no changes to these recommenda-
tions for 2014.
III. Assessment of overall cardiovascular risk in
hypertensive patients
Recommendations
1. Global cardiovascular risk should be assessed. Multifac-
torial risk assessment models can be used to predict more
accurately an individual’s global cardiovascular risk
(Grade A) and to use antihypertensive therapy more
efﬁciently (Grade D). In the absence of Canadian data to
determine the accuracy of risk calculations, avoid using ab-
solute levels of risk to support treatment decisions (Grade C).
2. Consider informing patients of their global risk to improve
the effectiveness of risk factor modiﬁcation (Grade B).
Consider also using analogies that describe comparative
risk such as “cardiovascular age,” “vascular age,” or “heart
age” to inform patients of their risk status (Grade B).Background. There are no changes to these recommenda-
tions for 2014. Risk calculators are freely available at: www.
myhealthcheckup.com (www.monbilansante.com) and www.
score-canada.ca. The latter Web site is the Systematic Cere-
brovascular and Coronary Risk Evaluation [SCORE]) risk
calculator. Although no risk engine developed from Canadiandata exists, Canadian cardiovascular disease prevalence and
mortality risk have been integrated into the original SCORE
risk engine to produce speciﬁc estimates for the Canadian
population (SCORE Canada).IV. Routine and optional laboratory tests for the
investigation of patients with hypertension
Recommendations
1. Routine laboratory tests that should be performed for the
investigation of all patients with hypertension include the
following:
i. Urinalysis (Grade D);
ii. Blood chemistry (potassium, sodium, and creatinine)
(Grade D);
iii. Fasting blood glucose and/or glycated hemoglobin
(A1C) (Grade D) (new recommendation);
iv. Fasting serum total cholesterol, high-density lipopro-
tein cholesterol, low-density lipoprotein cholesterol,
and triglycerides (Grade D); and
v. Standard 12-lead electrocardiography (Grade C).
2. Assess urinary albumin excretion in patients with diabetes
(Grade D).
3. All treated hypertensive patients should be monitored ac-
cording to the current Canadian Diabetes Association
guidelines for the new appearance of diabetes (Grade B).
4. During the maintenance phase of hypertension manage-
ment, tests (including those for electrolyte, creatinine, and
fasting lipid levels) should be repeated with a frequency
reﬂecting the clinical situation (Grade D).Background. When compared with oral glucose tolerance
testing, a systematic review suggests that A1C and fasting
glucose levels demonstrate comparable sensitivity and speciﬁcity
for diabetes detection.31 In a more recent analysis of more than
2000 adults at high risk for diabetes, Hu and colleagues
determined the sensitivity and speciﬁcity for diabetes of A1C
and fasting glucose to be virtually identical at the thresholds
evaluated. In addition, when both tests were combined, sensi-
tivity (96.5%) and speciﬁcity (96.3%) increased.32 The addi-
tion of A1C harmonizes the CHEP recommendations with
those of the Canadian Diabetes Association.33V. Assessment for renovascular hypertension
Recommendations
1. Patients presenting with  2 of the clinical clues listed
below, suggesting renovascular hypertension, should be
investigated (Grade D):
i. Sudden onset or worsening of hypertension and age >
55 or < 30 years;
ii. Presence of an abdominal bruit;
iii. Hypertension resistant to  3 drugs;
iv. Increase in serum creatinine level  30% associated
with use of an angiotensin-converting enzyme (ACE)
inhibitor or angiotensin receptor blocker (ARB);
v. Other atherosclerotic vascular disease, particularly in
patients who smoke or have dyslipidemia;
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tensive surges.
2. When available, the following tests are recommended to aid
in the usual screening for renal vascular disease: captopril-
enhanced radioisotope renal scan, Doppler sonography,
magnetic resonance angiography, and computed tomogra-
phy angiography (for those with normal renal function)
(Grade B). Captopril-enhanced radioisotope renal scan is
not recommended for those with CKD (glomerular ﬁltra-
tion rate < 60 mL/min/1.73m2) (Grade D).Background. There are no changes to these recommenda-
tions for 2014.VI. Endocrine hypertension
Recommendations
A. Hyperaldosteronism: screening and diagnosis
1. Screening for hyperaldosteronism should be considered
for the following patients (Grade D):
i. Hypertensive patients with spontaneous hypokale-
mia (Kþ < 3.5 mmol/L);
ii. Hypertensive patients with marked diuretic-
induced hypokalemia (Kþ < 3.0 mmol/L);
iii. Patients with hypertension refractory to treatment
with  3 drugs;
iv. Hypertensive patients found to have an incidental
adrenal adenoma.
2. Screening for hyperaldosteronism should include
assessment of plasma aldosterone and plasma renin
activity or plasma renin (Supplemental Table S7).
3. For patients with suspected hyperaldosteronism (on the
basis of the screening test; Supplemental Table S7, item iii.
Deﬁnition of a Positive ScreeningTest), a diagnosis of primary
aldosteronism should be established by demonstrating
inappropriate autonomous hypersecretion of aldosterone
using at least 1 of the manoeuvres listed in Supplemental
Table S7, item iv. Manoeuvres to demonstrate Autonomous
Hypersecretion of Aldosterone. When the diagnosis is estab-
lished, the abnormality should be localized using any of the
tests described in Supplemental Table S7, item v. Differ-
entiating Potential Causes of Primary Aldosteronism.
B. Pheochromocytoma: screening and diagnosis
1. If pheochromocytoma is strongly suspected, the
patient should be referred to a specialized hyperten-
sion centre, particularly if biochemical screening tests
(Supplemental Table S8) have already been found to
be positive (Grade D).
2. The following patients should be considered for
screening for pheochromocytoma (Grade D):
i. Patients with paroxysmal and/or severe (BP  180/
110 mm Hg) sustained hypertension refractory to
usual antihypertensive therapy;
ii. Patients with hypertension and multiple symptoms
suggestive of catecholamine excess (eg, headaches,
palpitations, sweating, panic attacks, and pallor);
iii. Patients with hypertension triggered by b-blockers,
monoamine oxidase inhibitors, micturition, or
changes in abdominal pressure;iv. Patients with incidentally discovered adrenal mass
and patients with hypertension and multiple
endocrine neoplasia 2A or 2B, von Recklinghausen
neuroﬁbromatosis, or von Hippel-Lindau disease;
v. For patients with positive biochemical screening tests,
localization of pheochromocytomas should involve the
use of magnetic resonance imaging (preferable),
computed tomography (if magnetic resonance imaging
is unavailable), and/or iodine I-131 meta-
iodobenzylguanidine scintigraphy (Grade C for each
modality).Background. There are no changes to these recommenda-
tions for 2014.
VII. HBPM
Recommendations
1. HBPM can be used in the diagnosis of hypertension
(Grade C).
2. The use of HBPM on a regular basis should be considered
for patients with hypertension, particularly those with:
i. Diabetes mellitus (Grade D);
ii. CKD (Grade C);
iii. Suspected nonadherence (Grade D);
iv. Demonstrated white coat effect (Grade C); or
v. BP controlled in the ofﬁce but not at home (masked
hypertension) (Grade C).
3. When white coat hypertension is suggested by HBPM, its
presence should be conﬁrmed by repeat HBPM (see
Recommendation 8 in this section) or ABPM before
treatment decisions are made (Grade D).
4. Patients should be advised to purchase and use only HBPM
devices that are appropriate for the individual and have met
standards of the Association for the Advancement of
Medical Instrumentation, the most recent requirements of
the British Hypertension Society protocol, or the Interna-
tional Protocol for validation of automated BP-measuring
devices. Patients should be encouraged to use devices with
data recording capabilities or automatic data transmission to
increase the reliability of reported HBPM (Grade D).
5. Home SBP values  135 mm Hg or DBP values  85 mm
Hg should be considered increased and associated with an
increased overall mortality risk analogous to ofﬁce SBP
readings of 140mmHg or DBP 90mmHg (Grade C).
6. Health care professionals should ensure that patients who
measure their BP at home have adequate training and, if
necessary, repeat training in measuring their BP. Patients
should be observed to determine that they measure BP
correctly and should be given adequate information about
interpreting these readings (Grade D).
7. The accuracy of all individual patients’ validated devices
(including electronic devices) must be regularly checked
against a device of known calibration (Grade D).
8. HBPM for assessing white coat hypertension or sustained
hypertension should be based on duplicate measures,
morning and evening, for an initial 7-day period. First-day
home BP values should not be considered (Grade D).Background. There are no changes to these recommenda-
tions for 2014.
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Recommendations
1. ABPM can be used in the diagnosis of hypertension (Grade
C). ABPM should be considered when an ofﬁce-induced
increase in BP is suspected in treated patients with:
i. BP that is not below target despite receiving appro-
priate chronic antihypertensive therapy (Grade C);
ii. Symptoms suggestive of hypotension (Grade C); or
iii. Fluctuating ofﬁce BP readings (Grade D).
2. Physicians should use only ABPM devices that have been
validated independently using established protocols (GradeD).
3. Therapy adjustment should be considered in patients with
a mean 24-hour ambulatory SBP of  130 mm Hg or
DBP of  80 mm Hg or a mean awake SBP of  135 mm
Hg or DBP of  85 mm Hg (Grade D).
4. The magnitude of changes in nocturnal BP should be
taken into account in any decision to prescribe or withhold
drug therapy based on ABPM (Grade C) because a decrease
in nocturnal BP of < 10% is associated with increased risk
of cardiovascular events.Background. There are no changes to these recommenda-
tions for 2014.
IX. Role of echocardiography
Recommendations
1. Routine echocardiographic evaluation of all hypertensive
patients is not recommended (Grade D).
2. An echocardiogram for assessment of left ventricular hy-
pertrophy is useful in selected cases to help deﬁne the
future risk of cardiovascular events (Grade C).
3. Echocardiographic assessment of left ventricular mass, and
of systolic and diastolic left ventricular function is recom-
mended for hypertensive patients suspected to have left
ventricular dysfunction or CAD (Grade D).
4. Patients with hypertension and evidence of heart failure should
have an objective assessment of left ventricular ejection fraction,
either using echocardiogram or nuclear imaging (Grade D).Background. There are no changes to these recommenda-
tions for 2014.
The CHEP 2014 Prevention and Treatment
Recommendations
Please note that treatment thresholds and targets refer to
OBPM. Please refer to section II. Criteria for Diagnosis of
Hypertension and Recommendations for Follow-up, for corre-
sponding values of other measurement methods.
I. Health behaviour management
Recommendations
A. Physical exercise
1. For nonhypertensive or stage 1 hypertensive in-
dividuals, the use of resistance or weight trainingexercise (such as free weight lifting, ﬁxed weight lifting,
or handgrip exercise) does not adversely inﬂuence BP
(Grade D). For nonhypertensive individuals (to reduce
the possibility of becoming hypertensive) or for hy-
pertensive patients (to reduce their BP), prescribe the
accumulation of 30-60 minutes of moderate intensity
dynamic exercise (eg, walking, jogging, cycling, or
swimming) 4-7 days per week in addition to the
routine activities of daily living (Grade D). Higher
intensities of exercise are not more effective (Grade D).B. Weight reduction
1. Height, weight, and waist circumference should be
measured and body mass index calculated for all adults
(Grade D).
2. Maintenance of a healthy body weight (body mass index
of 18.5 to 24.9, and waist circumference < 102 cm for
men and < 88 cm for women) is recommended for
nonhypertensive individuals to prevent hypertension
(Grade C) and for hypertensive patients to reduce BP
(Grade B). All overweight hypertensive individuals
should be advised to lose weight (Grade B).
3. Weight loss strategies should use a multidisciplinary
approach that includes dietary education, increased
physical activity, and behavioural intervention (Grade B).C. Alcohol consumption
1. To reduce BP, alcohol consumption should be in
accordance with Canadian low-risk drinking guidelines
in normotensive and hypertensive individuals. Healthy
adults should limit alcohol consumption to  2 drinks
per day, and consumption should not exceed 14 stan-
dard drinks per week for men and 9 standard drinks per
week for women (Grade B). (Note: One standard drink
is considered to be equivalent to 13.6 g or 17.2 mL of
ethanol or approximately 44 mL [1.5 oz] of 80 proof
[40%] spirits, 355 mL [12 oz] of 5% beer, or 148 mL
[5 oz] of 12% wine.)D. Dietary recommendations
1. It is recommended that hypertensive patients and
normotensive individuals at increased risk of devel-
oping hypertension consume a diet that emphasizes
fruits, vegetables, low-fat dairy products, dietary and
soluble ﬁbre, whole grains, and protein from plant
sources that is reduced in saturated fat and cholesterol
(Dietary Approaches to Stop Hypertension [DASH]
diet34-37; Supplemental Table S9) (Grade B).E. Sodium intake
1. To decrease BP, consider reducing sodium intake to-
ward 2000 mg (5 g of salt or 87 mmol of sodium) per
day (Grade A) (revised recommendation).F. Potassium, calcium, and magnesium intake
1. Supplementation of potassium, calcium, and magne-
sium is not recommended for the prevention or treat-
ment of hypertension (Grade B).G. Stress management
1. In hypertensive patients in whom stress might be a
contributor to high BP, stress management should be
considered as an intervention (Grade D). Individual-
ized cognitive-behavioural interventions are more likely
to be effective when relaxation techniques are used
(Grade B).
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the target sodium threshold from  1500 mg/d, is primarily
based on clinical trial evidence from 2 systematic reviews
published in 2013.38,39 The evidence focuses on BP as a
surrogate end point. The RTF noted the inconclusive nature
of the data examining morbidity and mortality end points and
awaits the results of further studies examining these end
points.40
He and colleagues38 examined 22 crossover and parallel-
arm randomized controlled trials that enrolled 999 hyper-
tensive individuals and compared reduced salt intake with
usual salt intake over a period of 4-52 weeks. Studies doc-
umenting a 40-120 mmol reduction in 24-hour urine so-
dium (equivalent to 920-2760 mg of sodium or 2.3-7 g of
salt) were included. The median baseline BP was 148/93
mm Hg and the median baseline 24-hour urine sodium
excretion was 162 mmol (range, 125-191 mmol). The
pooled estimated reduction in sodium intake between usual
intake and reduced intake was 75 mmol per 24 hours (95%
conﬁdence interval [CI], 53-117). Therefore, from baseline
levels in the usual care arm, interventions reduced sodium
intake toward a threshold of 87 mmol (ie, 162-75 mmol) or
2000 mg per day. Reduced intake led to a 5.39 mm Hg
reduction (95% CI, 4.15-6.62) in SBP and a 2.82 mm Hg
reduction (95% CI, 2.11-3.54) in DBP (pooled mean
effects).
The systematic review by Aburto and colleagues39 was
conducted on behalf of the World Health Organization
Nutrition Guidance Expert Advisory Group Subgroup on
Diet and Health. In 36 randomized controlled trials that
enrolled 5508 participants overall and 1478 subjects with
hypertension, a reduction in sodium intake resulted in a mean
3.39 mm Hg reduction (95% CI, 2.46-4.31 mm Hg) in SBP
in all subjects and a 4.06 mm Hg SBP reduction (95% CI,
2.96-5.15) in the subgroup with hypertension. A subgroup
analysis indicated that a reduction in sodium intake to less
than 2000 mg/d led to a decrease in SBP of 3.47 mm Hg
(95% CI, 0.76-6.18). Concurrent use of antihypertensive
medication did not appear to diminish the effect of decreasing
sodium intake.II. Indications for drug therapy for adults with
hypertension without compelling indications for speciﬁc
agents
Recommendations
1. Antihypertensive therapy should be prescribed for average
DBP measurements of  100 mm Hg (Grade A) or
average SBP measurements of  160 mm Hg (Grade A) in
patients without macrovascular target organ damage or
other cardiovascular risk factors.
2. Antihypertensive therapy should be strongly considered if
DBP readings average  90 mm Hg in the presence of
macrovascular target organ damage or other independent
cardiovascular risk factors (Grade A).
3. Antihypertensive therapy should be strongly considered if
SBP readings average  140 mm Hg in the presence of
macrovascular target organ damage (Grade C for 140-160
mm Hg; Grade A for > 160 mm Hg).4. Antihypertensive therapy should be considered in all pa-
tients meeting indications 1-3 in this section, regardless of
age (Grade B). Caution should be exercised in elderly pa-
tients who are frail.
5. In the very elderly (age  80 years) patients who do not
have diabetes or target organ damage, the SBP threshold
for initiating drug therapy is  160 mm Hg (Grade C)
(revised recommendation).Background. In 2013, CHEP introduced a < 150 mm Hg
SBP treatment target for adults 80 years of age or older (see
Recommendation 2 in section V. Goals of Therapy for Adults
With Hypertension Without Compelling Indications for Speciﬁc
Agents). This year, a  160 mm Hg pharmacotherapy treat-
ment initiation threshold was added. This recommendation
was based on data from the Hypertension in the Very Elderly
Trial (HYVET)41,42 and a meta-analysis by Gueyfﬁer and
colleagues.43 The HYVET enrolled 3845 hypertensive adults
(deﬁned as SBP of  160 mm Hg) aged 80 years or older and
randomized to active vs placebo treatment in which the active
treatment arm received indapamide 1.5 mg with or without
perindopril (2-4 mg) to achieve a target BP of < 150/80 mm
Hg. The primary outcome of the trial was stroke (fatal and
nonfatal), with all-cause mortality a predeﬁned secondary
outcome. The trial was stopped early (median follow-up was
1.8 years) when a planned interim analysis demonstrated
active treatment to be associated with a lower risk of stroke
(hazard ratio [HR], 0.59; 95% CI, 0.40-0.88) and all-cause
mortality (HR, 0.76; 95% CI, 0.62-0.93). However, the
ﬁnal time-to-event analysis, completed after the trial was
stopped and all end points had been counted,41 revealed that
the active treatment effect was no longer conclusive with
respect to stroke (HR, 0.70; 95% CI, 0.49-1.01), but that
there was still a conclusive 21% reduction in the risk of all-
cause mortality (HR, 0.79; 95% CI, 0.65-0.95). The
CHEP thus continues to recommend an SBP treatment
target of < 150 mm Hg, but in line with HYVET pro-
cedures, the SBP threshold for the initiation of treatment is
now speciﬁed as 160 mm Hg. As noted in the 2013 CHEP
recommendations, the HYVET population had low rates of
comorbid disease and adverse events during treatment. Sub-
jects with orthostatic hypotension were likely excluded
because standing SBP had to be  140 mm Hg at the last
visit before randomization. Therefore the RTF continues to
recommend caution when applying this recommendation to
frail elderly patients. For patients with SBP of 150-160 mm
Hg, providers should exercise clinical judgement when
deciding whether to initiate drug treatment and should note
that nonpharmacological therapy is still indicated for all
patients.
Further support for the  160 mm Hg SBP pharmaco-
logic treatment threshold in the very elderly population
comes from the pre-HYVET meta-analysis by Gueyfﬁer and
colleagues,43 evaluating the efﬁcacy of hypertension treat-
ment in patients  80 years of age. These investigators
included data from 7 trials that compared the efﬁcacy of
active treatment with either placebo, no treatment, or
decreased doses of active treatment on the primary outcome
of fatal and nonfatal stroke. Five of the 7 trials enrolled
patients with SBP levels  160 mm Hg. Among participants
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strokes and 34 stroke deaths, compared with 77 strokes and
28 stroke deaths among participants randomized to the
comparator groups (n ¼ 796). The risk for stroke was 34%
less (relative risk, 0.66; 95% CI, 0.48-0.92) among those in
the active treatment arms. Taken together, this meta-anal-
ysis43 and HYVET41,42 provide evidence that treatment
initiated at a threshold of  160 mm Hg reduces cardio-
vascular events and all-cause mortality in elderly patients.
III. Choice of therapy for adults with hypertension
without compelling indications for speciﬁc agents
Recommendations
A. Recommendations for individuals with diastolic and/or
systolic hypertension
1. Initial therapy should be a single-agent thiazide/thia-
zide-like diuretic (Grade A), a b-blocker (in patients
younger than 60 years; Grade B), an ACE inhibitor
(in non-black patients; Grade B), a long-acting calcium
channel blocker (CCB) (Grade B); or an ARB (Grade B).
If there are adverse effects, another drug from this group
should be substituted. Hypokalemia should be avoided
in patients treated with thiazide/thiazide-like diuretic
monotherapy (Grade C).
2. Additional antihypertensive drugs should be used if
target BP levels are not achieved with standard-dose
monotherapy (Grade B). Add-on drugs should be
chosen from ﬁrst-line choices. Useful choices include a
thiazide/thiazide-like diuretic or CCB with either: ACE
inhibitor, ARB or b-blocker (Grade B for the combi-
nation of thiazide/thiazide-like diuretic and a dihy-
dropyridine CCB; Grade C for the combination of
dihydropyridine CCB and ACE inhibitor; and Grade D
for all other combinations). Caution should be exer-
cised in combining a nondihydropyridine CCB and a
b-blocker (Grade D). The combination of an ACE
inhibitor and an ARB is not recommended (Grade A).
3. Combination therapy using 2 ﬁrst-line agents might
also be considered as initial treatment of hypertension
(Grade C) if SBP is 20 mm Hg greater than target or if
DBP is 10 mm Hg greater than target. However,
caution should be exercised in patients in whom a
substantial decrease in BP from initial combination
therapy is more likely to occur or in whom it would be
poorly tolerated (eg, elderly patients).
4. If BP is still not controlled with a combination of 2 or
more ﬁrst-line agents, or there are adverse effects, other
antihypertensive drugs may be added (Grade D).
5. Possible reasons for poor response to therapy (Supplemental
Table S10) should be considered (Grade D).
6. a-Blockers are not recommended as ﬁrst-line agents for
uncomplicated hypertension (Grade A); b-blockers are
not recommended as ﬁrst-line therapy for uncompli-
cated hypertension in patients 60 years of age or older
(Grade A); and ACE inhibitors are not recommended as
ﬁrst-line therapy for uncomplicated hypertension in
black patients (Grade A). However, these agents may be
used in patients with certain comorbid conditions or in
combination therapy.Background. There are no changes to these recommenda-
tions for 2014.
B. Recommendations for individuals with isolated systolic
hypertension
1. Initial therapy should be single-agent therapy with a
thiazide/thiazide-like diuretic (Grade A), a long-acting
dihydropyridine CCB (Grade A), or an ARB (Grade
B). If there are adverse effects, another drug from this
group should be substituted. Hypokalemia should be
avoided in patients treated with thiazide/thiazide-like
diuretic monotherapy (Grade C).
2. Additional antihypertensive drugs should be used if
target BP levels are not achieved with standard-dose
monotherapy (Grade B). Add-on drugs should be
chosen from ﬁrst-line options (Grade D).
3. If BP is still not controlled with a combination of 2 or
more ﬁrst-line agents, or there are adverse effects, other
classes of drugs (such as a-blockers, ACE inhibitors,
centrally acting agents, or nondihydropyridine CCBs)
may be added or substituted (Grade D).
4. Possible reasons for poor response to therapy (Supplemental
Table S10) should be considered (Grade D).
5. a-Blockers are not recommended as ﬁrst-line agents for
uncomplicated isolated systolic hypertension (Grade A);
and b-blockers are not recommended as ﬁrst-line
therapy for isolated systolic hypertension in patients
aged  60 years (Grade A). However, both agents may
be used in patients with certain comorbid conditions or
in combination therapy.Background. The recommendation addressing BP targets in
the very elderly (age  80 years) patients who do not have dia-
betes or target organ damage has been moved from section II.
Choice of Therapy for Adults With Hypertension Without
Compelling Indications for Speciﬁc Agents; B. Recommendations for
Individuals With Isolated Systolic Hypertension to section II. In-
dications for Drug Therapy for Adults With Hypertension Without
Compelling Indications for Speciﬁc Agents, because it does not
refer to choice of therapy but rather thresholds for initiation of
therapy.
IV. Global vascular protection therapy for adults with
hypertension without compelling indications for speciﬁc
agents
Recommendations
1. Statin therapy is recommended in hypertensive patients
with 3 or more cardiovascular risk factors as deﬁned in
Supplemental Table S11 (Grade A in patients > 40 years)
or with established atherosclerotic disease (Grade A
regardless of age).
2. Consideration should be given to the addition of low-dose
ASA therapy in hypertensive patients  50 years (Grade B)
(revised recommendation). Caution should be exercised if
BP is not controlled (Grade C).Background. The recommendation to consider ASA for the
primary prevention of cardiovascular disease in hypertensive
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Trial (HOT).44 In this trial, 18,790 patients aged 50-80
years (mean age, 61.5  7.5 years) with DBP levels between
100 and 115 mm Hg were randomized using a 3  2
factorial design to 1 of 3 DBP targets ( 90 vs  85 vs  80
mm Hg) and to ASA vs placebo. Over a mean follow-up time
of 3.8 years, ASA therapy reduced the incidence of major
cardiovascular events (MACE) from 10.5% to 8.9% (HR,
0.85; 95% CI, 0.73-0.99). When silent myocardial in-
farctions were included in the MACE end point, the overall
results were inconclusive (HR, 0.91; 95% CI, 0.79-1.04).44
It is unclear if silent infarctions were an a priori component
of the primary end point. On rereview of the trial and
protocol,45 the recommendation to give low-dose ASA in
hypertensive patients was downgraded to Grade B because of
this uncertainty.
A second alteration was made to the recommendation.
Previously, the RTF recommended that ASA treatment be
considered in all hypertensive individuals, with a Grade A
rating for those 50 years of age or older.28 This year, the
recommendation has been modiﬁed such that it is restricted
to hypertensive patients  50 years of age and is more
consistent with the population included in the HOT trial.
This change also took into consideration the beneﬁts of ASA
therapy in terms of reductions in MACE and prevention of
cancer and ASA-associated bleeding risks.46,47 The RTF did
not conduct in-depth modelling of these factors, which are
beyond the scope of CHEP’s mandate, but did note that an
age threshold of 50 years was consistent with the recom-
mendations of other organizations that have performed such
analyses.46,48V. Goals of therapy for adults with hypertension without
compelling indications for speciﬁc agents
Recommendations
1. The SBP treatment goal is a pressure level of < 140 mm
Hg (Grade C). The DBP treatment goal is a pressure level
of < 90 mm Hg (Grade A).
2. In the very elderly (age 80 years or greater), the BP target is
< 150 mm Hg (Grade C).Background. There are no changes to these recommenda-
tions for 2014. Recommendation V.2, which previously
appeared as Recommendation III.B.1, has been moved to this
section.VI. Treatment of hypertension in association with
ischemic heart disease
Recommendations
A. Recommendations for hypertensive patients with CAD
1. An ACE inhibitor or ARB is recommended for most
patients with hypertension and CAD (Grade A).
2. For patients with stable angina, b-blockers are preferred
as initial therapy (Grade B). CCBs may also be used
(Grade B).3. Short-acting nifedipine should not be used (Grade D).
4. For patients with CAD, but without coexisting systolic
heart failure, the combination of an ACE inhibitor and
ARB is not recommended (Grade B).
5. In high-risk patients, when combination therapy is
being used, choices should be individualized. The
combination of an ACE inhibitor and a dihydropyr-
idine CCB is preferable to an ACE inhibitor and a
thiazide/thiazide-like diuretic in selected patients
(Grade A).
6. When decreasing SBP to target levels in patients with
established CAD (especially if isolated systolic hy-
pertension is present), be cautious when the DBP is
 60 mm Hg because of concerns that myocardial
ischemia might be exacerbated (Grade D) (new
recommendation).
Background. Post hoc analyses of large clinical trials in pa-
tients with CAD suggest the existence of a possible J-curve, in
which BP lowering to less than a speciﬁc nadirdwhich varies
between studiesdis associated with an increased risk of cor-
onary events.49-51 This issue was discussed in detail in the
2013 CHEP recommendations.28 For 2014, after a rereview
of the evidence, the RTF voted to add a new recommendation
to advise caution if the DBP approaches 60 mm Hg or less
when striving to reach patient-speciﬁc SBP targets in patients
with concomitant CAD. This situation arises most commonly
when isolated systolic hypertension is present.
The recommendation to exercise caution with lowering
DBP to < 60 mm Hg is primarily derived from 3 studies;
post hoc analyses of the Systolic Hypertension in Europe
(Syst-Eur) trial,52 an observational coronary catheterization
study,53 and a systematic review of the beneﬁts of BP
reduction in patients with CAD.54 In the Syst-Eur trial,52
cardiovascular event rates were increased when on-treatment
DBP levels were  70 mm Hg (independent of SBP levels)
in older individuals (age  60 years) with CAD receiving
active antihypertensive treatment. This increase in cardiovas-
cular events appeared to reach statistical signiﬁcance at a DBP
value of approximately 60 mm Hg. An observational coronary
catheterization study53 demonstrated that when central DBP
was 60 mm Hg or less in hypertensive patients with CAD, the
probability of reduced coronary blood ﬂow distal to coronary
stenosis was increased. Finally, a recent systematic review54
examining the beneﬁcial and harmful effects of BP-lowering
drugs in patients with CAD indicated that further reduction
in cardiovascular disease event rates was small at SBP values
less than 140 mm Hg and should be weighed against the risk
of hypotension.
Thus, there is Grade D evidence supporting the possi-
bility of harm with excessive lowering of DBP in patients
with established CAD. An alternative explanation might be
that a lower DBP is a marker for frailty or medical illness and
not causally related to increased events.55 Nevertheless, the
RTF believed that the evidence was sufﬁciently robust to
warrant bringing this issue to the attention of practitioners.
The RTF wishes to emphasize that this suggests caution
when lowering BP but does not preclude BP-lowering,
especially in patients with moderate or severely increased
SBP levels. A cautious approach might involve observing
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blood ﬂow while lowering SBP. This new recommendation
does not apply to hypertensive patients without CAD.
Finally, even in the context of CAD, other diagnoses such as
diabetes or CKD might support further increases in antihy-
pertensive therapy to lower SBP even when DBP values are
 60 mm Hg.
B. Recommendations for patients with hypertension who
have had a recent myocardial infarction
1. Initial therapy should include a b-blocker and an ACE
inhibitor (Grade A).
2. An ARB can be used if the patient is intolerant of an
ACE inhibitor (Grade A in patients with left ventricular
systolic dysfunction).
3. CCBs may be used in patients after myocardial infarc-
tion when b-blockers are contraindicated or not effec-
tive. Nondihydropyridine CCBs should not be used
when there is heart failure, evidenced by pulmonary
congestion at time of examination or radiography
(Grade D).VII. Treatment of hypertension in association with heart
failure
Recommendations
1. In patients with systolic dysfunction (ejection fraction <
40%), ACE inhibitors (Grade A) and b-blockers (Grade A)
are recommended for initial therapy. Aldosterone antago-
nists (mineralocorticoid receptor antagonists) might be
added for patients with a recent cardiovascular hospitali-
zation, acute myocardial infarction, elevated B-type natri-
uretic peptide or N-terminal pro-B-type natriuretic peptide
level, or New York Heart Association class II-IV symptoms
(Grade A). Careful monitoring for hyperkalemia is rec-
ommended when adding an aldosterone antagonist to an
ACE inhibitor or ARB. Other diuretics are recommended
as additional therapy if needed (Grade B for thiazide/
thiazide-like diuretics for BP control, Grade D for loop
diuretics for volume control). Beyond considerations of BP
control, doses of ACE inhibitors or ARBs should be
titrated to those found to be effective in trials unless
adverse effects become manifest (Grade B).
2. An ARB is recommended if ACE inhibitors are not toler-
ated (Grade A).
3. A combination of hydralazine and isosorbide dinitrate is
recommended if ACE inhibitors and ARBs are contra-
indicated or not tolerated (Grade B).
4. For hypertensive patients whose BP is not controlled, an
ARB may be added to an ACE inhibitor and other anti-
hypertensive drug treatment (Grade A). Careful moni-
toring should be used if combining an ACE inhibitor and
an ARB because of potential adverse effects such as hy-
potension, hyperkalemia, and worsening renal function
(Grade C). Additional therapies might also include dihy-
dropyridine CCBs (Grade C).Background. There are no changes to these recommenda-
tions for 2014.VIII. Treatment of hypertension in association with
stroke
Recommendations
A. BP management in acute stroke (onset to 72 hours)
1. For patients with ischemic stroke not eligible for
thrombolytic therapy, treatment of hypertension in the
setting of acute ischemic stroke or transient ischemic
attack should not be routinely undertaken (Grade D).
Extreme BP increases (eg, SBP > 220 mm Hg or DBP
> 120 mm Hg) may be treated to reduce the BP by
approximately 15% (Grade D), and not more than
25%, over the ﬁrst 24 hours with gradual reduction
thereafter (Grade D). Avoid excessive lowering of BP
because this might exacerbate existing ischemia or
might induce ischemia, particularly in the setting of
intracranial arterial occlusion or extracranial carotid or
vertebral artery occlusion (Grade D). Pharmacological
agents and routes of administration should be chosen to
avoid precipitous decreases in BP (Grade D).
2. For patients with ischemic stroke eligible for thrombo-
lytic therapy, very high BP (> 185/110 mm Hg) should
be treated concurrently in patients receiving thrombo-
lytic therapy for acute ischemic stroke to reduce the risk
of secondary intracranial hemorrhage (Grade B).
B. BP management after acute stroke
1. Strong consideration should be given to the initiation of
antihypertensive therapy after the acute phase of a
stroke or transient ischemic attack (Grade A).
2. After the acute phase of a stroke, BP-lowering treatment
is recommended to a target of consistently < 140/90
mm Hg (Grade C).
3. Treatment with an ACE inhibitor and thiazide/thiazide-
like diuretic combination is preferred (Grade B).
4. For patients with stroke, the combination of an ACE
inhibitor and ARB is not recommended (Grade B).Background. There are no changes to these recommenda-
tions for 2014. However, 3 recent trials that examined SBP
targets in stroke were discussed,56-58 and are brieﬂy reviewed
herein. Two examined BP-lowering after spontaneous intra-
cerebral hemorrhage (ICH),56,57 and 1 addressed BP-lowering
2 or more weeks after a symptomatic lacunar infarction.58 The
results of these trials did not conclusively indicate beneﬁt for
greater BP reduction and no alterations were made to the
recommendations at the present time.
The Intensive Blood Pressure Reduction in Acute Cerebral
Hemorrhage Trial-2 (INTERACT-2) trial56 enrolled 2839
individuals within 6 hours of spontaneous ICH. Investigators
examined a strategy of lowering SBP within 1 hour of pre-
sentation to < 140 mm Hg compared with < 180 mm Hg;
these targets were to be maintained for at least 7 days. The
primary outcome was a composite of death and disability
deﬁned by a score of 3-6 on the modiﬁed Rankin scale 90
days after the event. The outcome rate was greater than ex-
pected in both trial arms and the between-group differences
were less than expected. There was a suggestion of a 13%
relative reduction (0.87; 95% CI, 0.75-1.01) in the primary
outcome favouring the lower SBP target group but as
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Therefore, the RTF was of the view that the strength of evi-
dence did not warrant a change in recommendations.
Intracerebral Hemorrhage Acutely Decreasing Arterial
Pressure Trial (ICH ADAPT)57 enrolled patients within 24
hours of a spontaneous ICH if their SBP was  150 mm Hg.
The SBP targets were < 150 mm Hg vs < 180 mm Hg. The
primary outcome was radiographically-determined peri-
hematoma relative cerebral blood ﬂow (rCBF) and the main
objective was to examine whether SBP-lowering had a detri-
mental effect on rCBF. Seventy-ﬁve participants were
enrolled. No conclusive differences in perihematoma rCBF
were demonstrated (perihematoma rCBF difference, 0.03;
95% CI, 0.018 to 0.078). The ipsilateral hemispheric rCBF
was slightly less in the lower BP target group (0.04 difference),
suggesting lower perfusion with a lower BP target, although
the magnitude of the difference was small. The investigators
interpreted their ﬁndings as suggesting no detrimental effect
on perihematoma rCBF with BP reduction after ICH.
The Secondary Prevention of Small Subcortical Strokes
(SPS3) trial58 enrolled 3020 patients with magnetic resonance
imaging-deﬁned symptomatic lacunar infarctions (ie, small
subcortical strokes) and without surgically amenable ipsilateral
carotid artery stenosis or high-risk cardioembolic sources.
Participants were enrolled 2 weeks after stroke and were ran-
domized to < 130 mm Hg vs 130-149 mm Hg SBP targets.
After 3.7 years, there was no conclusive difference in either the
incidence of recurrent stroke (HR, 0.81; 95% CI, 0.64-1.03)
or the occurrence of adverse events (orthostatic syncope HR,
2.19; 95% CI, 0.76-6.27; all adverse events HR, 1.53; 95%
CI, 0.80-2.93); the RTF noted, however, that the point esti-
mates suggested lower recurrent stroke rates but higher adverse
event rates in the < 130 mm Hg SBP target group.
IX. Treatment of hypertension in association with left
ventricular hypertrophy
Recommendations
1. Hypertensive patients with left ventricular hypertrophy
should be treated with antihypertensive therapy to lower
the rate of subsequent cardiovascular events (Grade C).
2. The choice of initial therapy can be inﬂuenced by the
presence of left ventricular hypertrophy (Grade D). Initial
therapy can be drug treatment using ACE inhibitors,
ARBs, long-acting CCBs, or thiazide/thiazide-like di-
uretics. Direct arterial vasodilators such as hydralazine or
minoxidil should not be used.Background. There are no changes to these recommenda-
tions for 2014.
X. Treatment of hypertension in association with
nondiabetic CKD
Recommendations
1. For patients with nondiabetic CKD, target BP is < 140/90
mm Hg (Grade B).
2. For patients with hypertension and proteinuric CKD
(urinary protein > 500 mg per 24 hours or albumin tocreatinine ratio > 30 mg/mmol), initial therapy should be
an ACE inhibitor (Grade A) or an ARB if there is intol-
erance to ACE inhibitors (Grade B).
3. Thiazide/thiazide-like diuretics are recommended as addi-
tive antihypertensive therapy (Grade D). For patients with
CKD and volume overload, loop diuretics are an alterna-
tive (Grade D).
4. In most cases, combination therapy with other antihyper-
tensive agents might be needed to reach target BP levels
(Grade D).
5. The combination of an ACE inhibitor and ARB is not
recommended for patients with nonproteinuric CKD
(Grade B).Background. There are no changes to these recommenda-
tions for 2014.
XI. Treatment of hypertension in association with
renovascular disease
Recommendations
1. Renovascular hypertension should be treated in the same
manner as hypertension without compelling indications,
except for caution in the use of ACE inhibitors or ARBs
because of the risk of acute renal failure in bilateral disease
or unilateral disease with a solitary kidney (Grade D).
2. Close follow-up and early intervention (angioplasty and
stenting or surgery) should be considered for patients with
uncontrolled hypertension despite therapy with  3 drugs,
deteriorating kidney function, bilateral atherosclerotic renal
artery lesions (or tight atherosclerotic stenosis in a single
kidney), or recurrent episodes of ﬂash pulmonary edema
(Grade D).Background. There are no changes to these recommenda-
tions for 2014.
XII. Treatment of hypertension in association with
diabetes mellitus
Recommendations
1. Persons with diabetes mellitus should be treated to attain
SBP of < 130 mm Hg (Grade C) and DBP of < 80 mm
Hg (Grade A) (these target BP levels are the same as the BP
treatment thresholds). Combination therapy using 2 ﬁrst-
line agents might also be considered as initial treatment
of hypertension (Grade B) if SBP is 20 mm Hg greater
than target or if DBP is 10 mm Hg greater than target.
However, caution should be exercised in patients in whom
a substantial decrease in BP is more likely or poorly
tolerated (eg, elderly patients and patients with autonomic
neuropathy).
2. For persons with cardiovascular or kidney disease,
including microalbuminuria, or with cardiovascular risk
factors in addition to diabetes and hypertension, an ACE
inhibitor or an ARB is recommended as initial therapy
(Grade A).
3. For persons with diabetes and hypertension not included in
other recommendations in this section, appropriate choices
Table 1. Considerations in the individualization of pharmacological therapy
Initial therapy Second-line therapy Notes and/or cautions
Hypertension without other compelling indications
Diastolic hypertension with or
without systolic hypertension
(target BP < 140/90 mm Hg)
Thiazide/thiazide-like diuretics, b-
blockers, ACE inhibitors, ARBs, or
long-acting CCBs (consider ASA
and statins in selected patients).
Consider initiating therapy with a
combination of ﬁrst-line drugs if the
BP is  20 mm Hg systolic or  10
mm Hg diastolic greater than target
Combinations of ﬁrst-line drugs Not recommended for monotherapy:
a-blockers, b-blockers in those  60
years of age, and ACE inhibitors in
black people. Hypokalemia should
be avoided in those prescribed
diuretics. ACE inhibitors, ARBs,
and direct renin inhibitors are
potential teratogens, and caution is
required if prescribing to women
with child-bearing potential.
Combination of an ACE-inhibitor
with an ARB is not recommended
Isolated systolic hypertension
without other compelling
indications (target BP for age
< 80 is < 140/90 mm Hg; for
age  80: target SBP is < 150
mm Hg
Thiazide/thiazide-like diuretics, ARBs
or long-acting dihydropyridine
CCBs
Combinations of ﬁrst-line drugs Same as diastolic hypertension with or
without systolic hypertension
Diabetes mellitus (target BP < 130/80 mm Hg)
Diabetes mellitus with
microalbuminuria,* renal disease,
cardiovascular disease, or
additional cardiovascular risk
factors
ACE inhibitors or ARBs Addition of a dihydropyridine CCB is
preferred over a thiazide/thiazide-
like diuretic
A loop diuretic could be considered in
hypertensive CKD patients with
extracellular ﬂuid volume overload
Diabetes mellitus not included in
the above category
ACE inhibitors, ARBs,
dihydropyridine CCBs, or thiazide/
thiazide-like diuretics
Combination of ﬁrst-line drugs. If
combination with ACE inhibitor is
being considered, a dihydropyridine
CCB is preferable to a thiazide/
thiazide-like diuretic
Normal urine microalbumin to
creatinine ratio < 2.0 mg/mmol
Cardiovascular disease (target BP < 140/90 mm Hg)
Coronary artery disease ACE inhibitors or ARBs; b-blockers
for patients with stable angina
Long-acting CCBs. When
combination therapy is being used
for high-risk patients, an ACE
inhibitor/dihydropyridine CCB is
preferred
Avoid short-acting nifedipine.
Combination of an ACE inhibitor
with an ARB is speciﬁcally not
recommended. Exercise caution
when decreasing SBP to target if
DBP is  60 mm Hg
Recent myocardial infarction b-Blockers and ACE inhibitors (ARBs
if ACE inhibitor-intolerant)
Long-acting CCBs if b-blocker
contraindicated or not effective
Nondihydropyridine CCBs should not
be used with concomitant heart
failure
Heart failure ACE inhibitors (ARBs if ACE
inhibitor-intolerant) and b-blockers.
Aldosterone antagonists
(mineralocorticoid receptor
antagonists) may be added for
patients with a recent cardiovascular
hospitalization, acute myocardial
infarction, elevated BNP or NT-
proBNP level, or NYHA class II-IV
symptoms
ACE inhibitor and ARB combined.
Hydralazine/isosorbide dinitrate
combination if ACE inhibitor and
ARB contraindicated or not
tolerated.
Thiazide/thiazide-like or loop diuretics
are recommended as additive
therapy. Dihydropyridine CCBs can
also be used
Titrate doses of ACE inhibitors and
ARBs to those used in clinical trials.
Carefully monitor potassium and
renal function if combining any of
ACE inhibitor, ARB, and/or
aldosterone antagonist
Left ventricular hypertrophy ACE inhibitor, ARB, long-acting CCB
or thiazide/thiazide-like diuretics.
Combination of additional agents Hydralazine and minoxidil should not
be used
Past stroke or TIA ACE inhibitor and a thiazide/thiazide-
like diuretic combination
Combination of additional agents Treatment of hypertension should not
be routinely undertaken in acute
stroke unless extreme BP increase.
Combination of an ACE inhibitor
with an ARB is not recommended
Nondiabetic CKD (target BP < 140/90 mm Hg)
Nondiabetic CKD with proteinuriay ACE inhibitors (ARBs if ACE
inhibitor-intolerant) if there is
proteinuria; diuretics as additive
therapy
Combinations of additional agents Carefully monitor renal function and
potassium for those taking an ACE
inhibitor or ARB. Combinations of
an ACE inhibitor and ARB are not
recommended in patients without
proteinuria
Renovascular disease Does not affect initial treatment
recommendations
Combinations of additional agents Avoid ACE inhibitors or ARBs if
bilateral renal artery stenosis or
unilateral disease with solitary
kidney
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Table 1. Continued.
Initial therapy Second-line therapy Notes and/or cautions
Other conditions (target BP < 140/90 mm Hg)
Peripheral arterial disease Does not affect initial treatment
recommendations
Combinations of additional agents Avoid b-blockers with severe disease
Dyslipidemia Does not affect initial treatment
recommendations
Combinations of additional agents d
Overall vascular protection Statin therapy for patients  3
cardiovascular risk factors or
atherosclerotic disease; low-dose
ASA in patients  50 years
d Caution should be exercised with the
ASA recommendation if BP is not
controlled
ACE, angiotensin-converting enzyme; ACR, albumin to creatinine ratio; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; BNP, B-type natriuretic
peptide; BP, blood pressure; CCB, calcium channel blocker; CKD, chronic kidney disease; DBP, diastolic blood pressure; NT, N-terminal; NYHA, New York
Heart Association; SBP, systolic blood pressure; TIA, transient ischemic attack.
*Microalbuminuria is deﬁned as persistent ACR > 2.0 mg/mmol.
y Proteinuria is deﬁned as urinary protein > 500 mg per 24 hours or ACR > 30 mg/mmol in 2 of 3 specimens.
Reproduced with permission of the Canadian Hypertension Education Program.
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ARBs (Grade B), dihydropyridine CCBs (Grade A), and
thiazide/thiazide-like diuretics (Grade A).
4. If target BP levels are not achieved with standard-dose
monotherapy, additional antihypertensive therapy should
be used. For persons in whom combination therapy with
an ACE inhibitor is being considered, a dihydropyridine
CCB is preferable to a thiazide/thiazide-like diuretic
(Grade A).Background. There are no changes to these recommenda-
tions for 2014.
XIII. Adherence strategies for patients
Recommendations
1. Adherence to an antihypertensive prescription can be
improved by a multipronged approach (Supplemental
Table S12).Background. There are no changes to these recommenda-
tions for 2014.
XIV. Treatment of secondary hypertension because of
endocrine causes
Recommendations
1. Treatment of hyperaldosteronism and pheochromocytoma
are outlined in Supplemental Tables S7 and S8,
respectively.Background. There are no changes to these recommenda-
tions for 2014.Implementation
The implementation task force conducts an extensive
knowledge translation effort to enhance uptake and applica-
bility of these recommendations. These efforts include
knowledge exchange forums, targeted educational materials
for primary care providers and patients, and freely availableslide kits and summary documents of all recommendations on
the Canadian Hypertension Society Web site, Hypertension
Canada (www.hypertension.ca). Documents are available in
French and English, and some documents are translated into
other languages. The implementation task force also regularly
receives feedback from end users to improve guideline pro-
cesses and content. Although the number of primary care
providers who directly receive CHEP materials on a regular
basis has dramatically increased, CHEP is continuing to
address the challenge of identifying and reaching all active
primary care providers across Canada, through use of the
Hypertension Canada Web site, “Train the Trainer” teaching
sessions, and wide dissemination of educational materials.
The CHEP outcomes task force conducts hypertension
surveillance studies and reviews existing Canadian health
surveys to identify gaps between current and best practices.Future Directions
Table 1 contains a summary of pharmacological manage-
ment recommendations for hypertension. The present article
represents the 14th iteration of the annually updated CHEP
recommendations for the management of hypertension. The
RTF will continue to conduct systematic reviews of the
clinical trial evidence and update these recommendations
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